Multidrug resistance gene expression and ABCB1 SNPs in plasma cell myeloma

Leukemia Research

Volumn 35, Issue 11, 2011, Pages 1457-1463

  Drain, Stephen ^a,b   Flannely, Louise ^a,b   Drake, Mary B ^a   Kettle, Paul ^a   Orr, Nick ^c   Bjourson, Anthony J ^b   Catherwood, Mark A ^a,b   Alexander, H Denis ^a,b  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

ABC transporters; Gene expression; Haplotype; Multidrug resistance; Overall survival; Plasma cell myeloma

Indexed keywords

CYTOTOXIC AGENT; MESSENGER RNA;

ABCB1 GENE; ABCB4 GENE; ABCC1 GENE; ABCG2 GENE; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RELAPSE; CANCER STAGING; FEMALE; GENE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; GUSB GENE; HAPLOTYPE; HOUSEKEEPING GENE; HUMAN; LRP1 GENE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL;

ADULT; AGED; ATP-BINDING CASSETTE TRANSPORTERS; DNA, NEOPLASM; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LINKAGE DISEQUILIBRIUM; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 80053959088     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.033     Document Type: Article

References (35)

1. Sanford S., Deborshi R., Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci 1994, 91:3497-3504.
2. Fletcher J.I., Haber M., Henderson M.J., Norris M.D. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010, 10(February (2)):147-156.
3. Coley H.M. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol 2010, 596:341-358.
4. Ma P., Dong X., Swadley C.L., Gupte A., Leggas M., Ledebur H.C., et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol 2009, 5(April (2)):151-161.
5. Borst P., Evers R., Kool M., Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta 1999, 1461(December (2)):347-357.
6. Johnstone R.W., Ruefli A.A., Smyth M.J. Multiple physiological functions for multidrug transporter P-glycoprotein?. Trends Biochem Sci 2000, 25(January (1)):1-6.
7. Pavek P., Fendrich Z., Staud F. Physiologic function of P-glycoprotein. Cesk Fysiol 2002, 51(August (3)):99-107.
8. Zhu B.T. A novel hypothesis for the mechanism of action of P-glycoprotein as a multidrug transporter. Mol Carcinog 1999, 25(May (1)):1-13.
9. Chaudhary P.M., Mechetner E.B., Roninson I.B. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992, 80(December (11)):2735-2739.
10. Grogan T.M., Spier C.M., Salmon S.E., Matzner M., Rybski J., Weinstein R.S., et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993, 81(January (2)):490-495.
11. Wuchter C., Leonid K., Ruppert V., Schrappe M., Buchner T., Schoch C., et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000, 85(July (7)):711-721.
12. Yamaguchi M., Mizutani M., Miwa H., Kita K. P-glycoprotein expression in hematological malignancies. Rinsho Ketsueki 1995, 36(June (6)):567-572.
13. Tiirikainen M.I., Elonen E., Ruutu T., Jansson S.E., Krusius T. Clinical significance of P-glycoprotein expression in acute leukaemia as analysed by immunocytochemistry. Eur J Haematol 1993, 50(May (5)):279-285.
14. Lee C.A., Cook J.A., Reyner E.L., Smith D.A. P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol 2010, 6(May (5)):603-619.
15. Hoellein A., Decker T., Bogner C., Oelsner M., Hauswald S., Peschel C., et al. Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status. J Cancer Res Clin Oncol 2010, 136(March (3)):403-410.
16. Raaijmakers M.H., de Grouw E.P., Heuver L.H., van der Reijden B.A., Jansen J.H., Scheffer G., et al. Impaired breast cancer resistance protein mediated drug transport in plasma cells in multiple myeloma. Leuk Res 2005, 29(December (12)):1455-1458.
17. Prime-Chapman H.M., Fearn R.A., Cooper A.E., Moore V., Hirst B.H. Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial caco-2 cells. J Pharmacol Exp Ther 2004, 311(November (2)):476-484.
18. Matthews C., Catherwood M.A., Larkin A.M., Clynes M., Morris T.C., Alexander H.D. MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leuk Lymphoma 2006, 47(November (11)):2308-2313.
19. Jamroziak K., Mlynarski W., Balcerczak E., Mistygacz M., Trelinska J., Mirowski M., et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004, 72(May (5)):314-321.
20. Porcelli L., Lemos C., Peters G.J., Paradiso A., Azzariti A. Intracellular trafficking of MDR transporters and relevance of SNPs. Curr Top Med Chem 2009, 9(2):197-208.
21. Siegmund W., Ludwig K., Giessmann T., Dazert P., Schroeder E., Sperker B., et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002, 72(November (5)):572-583.
22. Jamroziak K., Balcerczak E., Smolewski P., Robey R.W., Cebula B., Panczyk M., et al. MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep 2006, 58(September-October (5)):720-728.
23. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000, 97(March (7)):3473-3478.
24. Salama N.N., Yang Z., Bui T., Ho R.J. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci 2006, 95(October (10)):2293-2308.
25. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315(January (5811)):525-528.
26. Buda G., Maggini V., Galimberti S., Martino A., Giuliani N., Morabito F., et al. MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol 2007, 137(June (5)):454-456.
27. Drain S., Catherwood M.A., Orr N., Galligan L., Rea I.M., Hodkinson C., et al. ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma. Leuk Lymphoma 2009, 50(April (4)):566-570.
28. Maggini V., Buda G., Martino A., Presciuttini S., Galimberti S., Orciuolo E., et al. MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics 2008, 18(May (5)):383-389.
29. Hui R.C., Francis R.E., Guest S.K., Costa J.R., Gomes A.R., Myatt S.S., et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther 2008, 7(March (3)):670-678.
30. Li Y., Yuan H., Yang K., Xu W., Tang W., Li X. The structure and functions of P-glycoprotein. Curr Med Chem 2010, (January).
31. Conte L.G., Figueroa M.G., Lois V.V., Cabrera C.M.E., Leon R.A., Garcia L.H., et al. Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system. Rev Med Chil 2008, 136(January (1)):7-12.
32. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975, 36(September (3)):842-854.
33. Dispenzieri A., Rajkumar S.V., Gertz M.A., Fonseca R., Lacy M.Q., Bergsagel P.L., et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007, 82(March (3)):323-341.
34. Buda G., Martino A., Maggini V., Orciuolo E., Galimberti S., Gentile M., et al. MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma. Acta Haematol 2009, 122(1):42-45.
35. Sonneveld P., Nooter K., Burghouts J.T., Herweijer H., Adriaansen H.J., van Dongen J.J. High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. Blood 1992, 79(March (6)):1496-1500.